Half-Life

Half-Life

In pharmacology, the half-life (t1/2) of a drug refers to the time it takes for the plasma concentration of that drug to decrease to 50% of its peak value. Half-life is a fundamental pharmacokinetic parameter that directly influences how often a medication needs to be administered: drugs with short half-lives require more frequent dosing, while those with long half-lives can be given less frequently.

The half-life of a drug is determined by two primary factors: clearance (how quickly the body eliminates the drug) and volume of distribution (how extensively the drug distributes into body tissues). For peptide-based therapeutics like retatrutide, pharmaceutical engineers have employed strategies such as fatty acid acylation and amino acid modifications to extend the half-life far beyond that of the native hormones. While endogenous GLP-1 has a half-life of approximately two minutes, retatrutide’s engineered structure provides a half-life of roughly six days, which supports once-weekly subcutaneous administration.

Understanding half-life is also important for interpreting steady-state pharmacokinetics. For any drug given at regular intervals, it takes approximately four to five half-lives to reach steady-state plasma concentrations. For retatrutide, this means approximately four to five weeks of weekly administration are needed before drug levels stabilize, which has implications for the expected onset of therapeutic effects and the design of dose-escalation protocols in clinical trials.